B[Preview: The State Council Information Office holds a press conference on decisive progress in promoting the construction of a healthy China] September 12th, the State Council Information Office will hold a series of press conferences with the theme of "Getting Started with the 15th Five-Year Plan" at 10 a.m. on September 14, 2026 (Monday). Lei Haichao, director of the National Health Commission, Liu Jinfeng, deputy director of the National Health Commission and director of the State Administration of Traditional Chinese Medicine, Shen Hongbing, deputy director of the National Health Commission and director of the National Bureau of Disease Control and Prevention, and Guo Yanhong, spokesperson and deputy director of the National Health Commission, introduced the decisive progress in promoting the construction of a healthy China and answered reporters' questions. B[Four departments regulate the management of anesthesia and psychotropic drugs in medical institutions] On September 9, four departments including the National Health Commission and the State Administration of Traditional Chinese Medicine jointly issued the "Regulations on the Management of Narcotic Drugs and Psychotropic Drugs in Medical Institutions". There are 11 chapters and 73 management regulations in total, focusing on key aspects such as the procurement, storage, issuance, use, recycling, and destruction of anesthetic drugs, and detailing and improving various management requirements. Medicinal narcotic drugs and psychotropic drugs are drugs subject to special management in accordance with laws and regulations in China. They have the dual attributes of being necessary for clinical diagnosis and treatment and prone to dependence and addiction. Their safe and reasonable use is related to the lives and health of the people and social harmony and stability. What are the characteristics of management regulations? First, the scope of application is expanded from medicinal narcotic drugs and Category I psychotropic drugs to all medicinal anesthetic drugs (including medicinal narcotic drugs, Category I psychotropic drugs and Category II psychotropic drugs). The second is to refine the internal management system and training and assessment requirements of medical institutions, and improve the management of key departments such as pharmacies, anesthesiology departments, and operating rooms, as well as working mechanisms for recycling, destruction, and safety emergency response.
Third, relevant provisions on informed consent have been added. Prescribing anesthetic drugs to minors requires the written informed consent of their guardians. The fourth is to actively play the role of informatization in the management of anesthetic drugs in medical institutions. Promote the use of digital intelligence technology to strengthen the full-process management of anesthetic drugs in medical institutions and improve management efficiency. It is reported that the management regulations will be implemented from October 1, 2026. B[Morning session on the fourth day of the 2026 State Talks: Kelun Pharmaceutical, Tasly, etc. enter negotiations] September 8th, at about 8 o'clock today, the morning session on the fourth day of the 2026 National Basic Medical Insurance Drug List Negotiation Bidding and Commercial Insurance Innovative Drug List Price Negotiation officially opened. Reporters observed at the scene that Kelun Pharmaceutical, Luye Pharmaceutical, Chia Tai Tianqing, Shenwei Pharmaceutical, Jiangxi Pharmaceutical Capital Zhangshu, Weikang Pharmaceutical, Tasly, Jilin Aodong, etc. were about 20 Representatives from several companies lined up to enter the venue. This is also the first time since the first day of the state-to-state talks that a large number of traditional Chinese medicine companies and Western medicine companies have begun negotiations to enter the country at the same time. (Reporters Lu Afeng and Yu Miao) B[Six departments: Encourage tea, traditional Chinese medicine, silk and other famous products to enter port exit duty-free shops, departure tax refund shops, city duty-free shops, and high-end supermarkets in accordance with the law and regulations] On September 7, six departments including the Ministry of Industry and Information Technology recently jointly issued the "Opinions on Promoting the High-Quality Development of Historical Classic Industries." Opinions put forward to build a multi-channel overseas platform. Give full play to the role of multilateral cooperation mechanisms such as the high-quality Belt and Road Initiative, the Regional Comprehensive Economic Partnership Agreement, and the Shanghai Cooperation Organization, make good use of open platforms such as the Pilot Free Trade Zone and Hainan Free Trade Port, and strengthen international cooperation in technology, standards, markets and other fields. Organize and implement the "Global Premiere of Classic Brands" to support classic and famous enterprises in launching new products, displaying transactions, and disseminating promotions on key exhibition platforms such as the China International Import Expo, China International Fair for Trade in Services, and China International Consumer Goods Expo. Encourage tea, traditional Chinese medicine, silk and other famous products to enter port exit duty-free shops, departure tax refund shops, city duty-free shops, and high-end supermarkets in accordance with laws and regulations, and support classic famous companies in setting up brand experience centers abroad. B[National Medical Insurance Administration: Will continue to expand the coverage of centralized procurement and guide fair and rational competition in the industry] On September 4, the State Council Information Office held a series of press conferences with the theme of "Starting the 15th Five-Year Plan" to introduce the situation of promoting high-quality development of medical insurance and better serving China-style modernization. According to reports, a total of 12 batches of centralized procurement of drugs have been carried out at the national level, covering 555 types of drugs; 6 batches of centralized procurement of high-value medical consumables have been carried out, covering 142 types of consumables in 9 categories. At the same time, provincial-level centralized procurement has been carried out in various places to continue to facilitate the public's access to high-quality and affordable pharmaceutical products.
In the next step, the medical insurance department will continue to expand the coverage of centralized purchasing. Regularly carry out the centralized procurement of drugs and medical consumables organized by the state, guide local governments to further promote inter-provincial alliance procurement, continue to adhere to the principle of "no centralized procurement of new drugs, centralized procurement of non-new drugs", include more varieties with large clinical use and inflated prices into the scope of procurement, continue to deepen the fields of traditional Chinese medicine, biological drugs, medical consumables and other fields, and effectively reduce the cost burden of the people. At the same time, we adhere to the principles of "stabilizing clinical practice, ensuring quality, resisting involution, and preventing bid-rigging", optimize procurement rules, pay more attention to clinical needs, and guide the industry to compete fairly and rationally through "extremely high prices will lead to elimination, and abnormally low prices without quantity", and resolutely combat bid-rigging in the field of centralized pharmaceutical procurement. In addition, it is required to work together to ensure quality and stable supply. Collaboration with the drug regulatory department will be strengthened to strictly enforce the quality threshold requirements for centralized procurement. We will continue to carry out "full coverage" of inspections of enterprises selected for national centralized procurement and variety sampling, and seriously deal with companies that find problems. Supervise the selected enterprises to fulfill their main responsibilities in ensuring supply and effectively ensure the fulfillment of supply contracts.
Supervision and monitoring will be carried out focusing on the standardization of centralized collection and reporting volume and the implementation of winning results, while optimizing assessments to avoid "one size fits all". Promote direct settlement between medical insurance and pharmaceutical companies, promote centralized procurement of selected drugs into primary medical institutions, private hospitals, and designated retail pharmacies, and expand the scope of public access.
— All loaded —
